RBR-9d5n4g招募中未知
Combined, At-home and In-Office Dental Bleaching: efficacy, clinical parameters follow-up and enamel evaluation of calcium and phosphorus concentrations
Faculdade Centro de Pesquisa São Leopoldo Mandic0 个研究点开始时间: 2018年5月24日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 招募中
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Intervention
入排标准
- 年龄范围
- 18Y 至 30Y（—）
入选标准
- •aged 18 to 30 years, the presence of at least 20 teeth and the presence of the elements 11, 21, 22, 12, 13, 23, 31, 32, 33, 41, 42, 43 healthy or at most 1 / 6 restored labial surface.
排除标准
- •The exclusion criteria of this study are: teeth with initial color B1 assessed by spectrophotometer (VITA Easyshade® Advance, Vita, Germany), patients with removable dentures or fixed and removable orthodontic appliances participants pregnant or breastfeeding, smoking participants, participants with prior dentinal sensitivity, presence of active caries lesions in enamel and dentin, periodontal disease and other oral lesions, pigmented teeth tetracycline and patients who received prior bleaching treatment.
研究者
相似试验
进行中（未招募）
不适用
A prospective, multi-centre, randomised, double-blind, placebo-controlled comparison of intravenous dexmedetomidine with haloperidol in treatment of hyperactive delirium after heart surgery. - Dex-in-delirPostoperative hyperactive deliriumMedDRA version: 12.0Level: LLTClassification code 10000702Term: Acute deliriumMedDRA version: 12.0Level: LLTClassification code 10049989Term: Agitation postoperativeMedDRA version: 12.0Level: LLTClassification code 10056436Term: Psychomotor agitationMedDRA version: 12.0Level: LLTClassification code 10049987Term: Confusion postoperativeEUCTR2008-007384-17-SESten Walther75
进行中（未招募）
1 期
A prospective, multicentre, randomised, double-blind, placebo-controlled, phase 2a study to compare the efficacy and the safety of 24-week treatment with masitinib versus placebo in patients with severe Chronic Obstructive Pulmonary Disease (COPD)Patients with severe COPDEUCTR2012-005586-13-ESAB SCIENCE30
进行中（未招募）
不适用
A prospective, multicentre, randomised, double-blind, placebo-controlled, phase 2a study to compare the efficacy and the safety of 24-week treatment with masitinib at 6 mg/kg/day versus placebo in patients with severe Chronic Obstructive Pulmonary Disease (COPD)severe Chronic Obstructive Pulmonary Disease (COPD)MedDRA version: 12.1Level: LLTClassification code 10009033Term: Chronic obstructive pulmonary diseaseEUCTR2010-021495-29-FRAB Science
进行中（未招募）
1 期
A study of a new iron medication for people with Crohn's Disease that is in remission and anaemia (low number of healthy red blood cells), who cannot use other oral iron medications either because they do not work, or because they cause side effects. (AEGIS 2)Iron deficiency anaemia in quiescent Crohn's DiseaseMedDRA version: 14.1 Level: PT Classification code 10022972 Term: Iron deficiency anaemia System Organ Class: 10005329 - Blood and lymphatic system disordersMedDRA version: 14.1 Level: LLT Classification code 10002062 Term: Anaemia iron deficiency System Organ Class: 10005329 - Blood and lymphatic system disordersEUCTR2010-023589-39-GBIron Therapeutics (Switzerland) AG128
进行中（未招募）
1 期
clinical trial to assess efficacy and safety of masitinib in the treatment of Chronic Obstructive Pulmonary DiseaseSevere Chronic Obstructive Pulmonary Disease (COPD)MedDRA version: 20.0 Level: PT Classification code 10009033 Term: Chronic obstructive pulmonary disease System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersEUCTR2012-005586-13-SKAB Science45